CJC-1295 (with DAC) vs MOTS-c

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

CJC-1295 (with DAC)MOTS-c
CategoryPeptidesPeptides
Standard DoseResearch indicates 2 mg administered once weekly via subcutaneous injection.Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
TimingEvening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
Cycle Duration12-24 week cycles with 4-8 week breaks between cycles.8-16 week cycles.
Evidence Levelmoderate_humanEmerging (strong preclinical)

Mechanism

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.

Standard Dosing

Research indicates 2 mg administered once weekly via subcutaneous injection.

Timing

Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.

Cycle Duration

12-24 week cycles with 4-8 week breaks between cycles.

Side Effects

  • Water retention
  • Tingling/numbness in extremities
  • Joint pain
  • Increased hunger
  • Injection site reactions
  • Potential insulin resistance with prolonged use

Contraindications

  • Active cancer or history of cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6
B

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →